3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
27
Triple Negative Breast Neoplasms
9
Sarcoma
5
Neoplasm Metastasis
4
Liposarcoma
3
Urinary Bladder Neoplasms
2
Leiomyosarcoma
2
Inflammatory Breast Neoplasms
2
Carcinoma, Transitional Cell
2
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Refractory Solid Tumors
1
Recurrence
1
Metastatic HER2-positive Breast Cancer
1
Inoperable Locally Advanced HER2-Negative Breast Cancer
1
Histiocytoma, Malignant Fibrous
1
Hemangiosarcoma
1
Hemangioendothelioma, Epithelioid
1
HR+HER2- Breast Cancer
1
HER2-low Breast Cancer
1
Fludzoparib" and Anti-angiogenic
1
Colorectal Neoplasms
1
Brest Cancer
1
Brain Neoplasms
1
Advanced Breast Cancer
1
Interventions
pembrolizumab
137
Nivolumab
116
Ipilimumab
68
Cyclophosphamide
33
Specimen Handling
31
Magnetic Resonance Spectroscopy
28
trametinib
23
binimetinib
22
fludarabine
21
Interleukin-2
20
dabrafenib
19
relatlimab
17
encorafenib
17
Biopsy
17
CTLA-4 Antigen
16
cemiplimab
15
atezolizumab
15
aldesleukin
15
Radiosurgery
15
fludarabine phosphate
14
Opdualag
14
Radiotherapy
11
lenvatinib
10
Blood Specimen Collection
10
lifileucel
9
Paclitaxel
8
Cisplatin
8
Bevacizumab
8
spartalizumab
7
cobimetinib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Melanoma
×
eribulin
×
1 year
×
Clear all
No trials found.